Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report report published on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 5.0 %

Shares of NASDAQ:EVOK opened at $2.10 on Friday. The company has a 50 day moving average of $3.60 and a 200-day moving average of $4.41. The firm has a market cap of $3.14 million, a P/E ratio of -0.19 and a beta of 0.30. Evoke Pharma has a twelve month low of $1.94 and a twelve month high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC lifted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities & Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.